DarioHealth (NASDAQ:DRIO) Stock Rating Lowered by Wall Street Zen

DarioHealth (NASDAQ:DRIO) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

Other research analysts have also issued reports about the company. Stifel Nicolaus set a $16.00 price objective on DarioHealth in a research report on Friday, November 14th. Cowen reiterated a “hold” rating on shares of DarioHealth in a report on Friday, November 14th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of DarioHealth in a research report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $32.00.

DarioHealth Trading Down 6.8%

NASDAQ DRIO opened at $11.89 on Friday. The firm has a market capitalization of $80.47 million, a price-to-earnings ratio of -1.07 and a beta of 1.08. The company has a debt-to-equity ratio of 0.41, a quick ratio of 4.02 and a current ratio of 4.55. DarioHealth has a one year low of $5.93 and a one year high of $31.00. The company’s 50 day moving average price is $13.43 and its 200 day moving average price is $12.48.

Institutional Investors Weigh In On DarioHealth

An institutional investor recently raised its position in DarioHealth stock. XTX Topco Ltd raised its holdings in DarioHealth Corp. (NASDAQ:DRIO) by 229.0% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 62,511 shares of the company’s stock after purchasing an additional 43,513 shares during the period. XTX Topco Ltd owned about 0.14% of DarioHealth worth $42,000 as of its most recent SEC filing. 33.39% of the stock is owned by institutional investors.

DarioHealth Company Profile

DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.